|
|
|
Volumn 22, Issue 2 B, 2002, Pages 1337-1340
|
|
Neutropenic infections add significant costs to palliative chemotherapy in breast cancer
a
a
|
|
Author keywords
Breast cancer; Clinical benefit; Health resources utilization; Palliative chemotherapy
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIFUNGAL AGENT;
ANTIVIRUS AGENT;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
EPIRUBICIN;
FLUOROURACIL;
GRANISETRON;
GRANULOCYTE COLONY STIMULATING FACTOR;
METHOTREXATE;
PREDNISOLONE;
ADULT;
AGED;
ALOPECIA;
ANEMIA;
ARTICLE;
BLOOD TRANSFUSION;
BREAST CARCINOMA;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PALLIATIVE THERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DRUG COST;
DRUG EFFICACY;
FATIGUE;
FLUID RETENTION;
HEALTH CARE UTILIZATION;
HOSPITALIZATION;
HUMAN;
LENGTH OF STAY;
LEUKOPENIA;
MAJOR CLINICAL STUDY;
MEDICAL RECORD;
MUCOSA INFLAMMATION;
NAUSEA;
NEUTROPENIA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
SKIN TOXICITY;
STOMATITIS;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
VOMITING;
ADULT;
AGED;
ANTI-INFECTIVE AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
EPIRUBICIN;
FEMALE;
HUMANS;
INFECTION;
MIDDLE AGED;
NEUTROPENIA;
PACLITAXEL;
PALLIATIVE CARE;
TAXOIDS;
|
|
EID: 0036322142
PISSN: 02507005
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (15)
|
